NY-PYRAMID-ANALYTICS
30.11.2022 09:01:54 CET | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, continues to consistently execute on its strategy to rapidly expand channel partnerships with complementary technology companies, independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI) across the United Kingdom and Ireland (UKI). The London-based software company today announced new partnerships with Datazed Associates, Data Reply, and Digital Data Consultancy.
Key Points:
- Pyramid Analytics signed deals with new partners serving the IT needs of mid-size and large enterprises across the UKI: Datazed Associates (Referral Partner); Digital Data Consultancy (Systems Integrator); and Data Reply (Consultancy, Systems Integrator).
- The channel partner programme is the backbone of Pyramid’s UKI operations, accounting for a significant segment of UK revenue.
- Pyramid Analytics is recognized for channel excellence. The company was a CRN Channel Awards 2022 finalist.
- To learn more about becoming a Pyramid partner in the UK and Ireland, contact Bill Clayton, Vice President, Global Partnerships, at bill.clayton@pyramidanalytics.com.
Meet Pyramid Analytics’ New Partners
Datazed Associates is a boutique data consultancy specialising in data governance and data quality. The company’s network of experienced professionals has a strong track record in the insurance industry, having supported general insurers, Lloyd’s market firms, brokers and reinsurers.
Data Reply is the Reply group company offering a broad range of advanced analytics and AI-powered data services. Data Reply operates across industries and business functions to achieve meaningful outcomes through effective use of data.
Digital Data Consultancy provides consulting services in the areas of data management, data science, and digital experience. The company helps clients in retail, hospitality, healthcare, banking and consumer goods to master and reimagine their data, create new value, and differentiate and profit in the digital economy.
Pyramid Analytics Delivers Value for Partners
Partnerships are critical to Pyramid’s ability to scale growth. In turn, partners get access to the Pyramid Decision Intelligence Platform, an innovative augmented analytics platform which has garnered analyst accolades for its ability to transform businesses.
Pyramid Partners benefit from a range of resources to help them effectively market, sell, and deliver the Pyramid Platform, integrated solutions, and services. These include the Pyramid Partner Portal, a one-stop shop for deal management, market education content, co-branded marketing materials, and interactive tools and resources; and the Pyramid Learning Hub for self-guided and expert-led courses, and Pyramid Partner Certification programs.
United Kingdom the World’s “Next Silicon Valley”?
Jeremy Hunt, the UK’s Chancellor of the Exchequer, outlined a number of priorities in his Autumn Statement on 17 November. These included his plan to “turn the United Kingdom into the world’s next Silicon Valley.” Pyramid Analytics has operated and flourished in the UK for nearly five years and are proud of the company’s contribution to achieving this goal. The advanced analytics platform company has added three executives and numerous business development roles in its London office in 2022.
2022 has been momentous for Pyramid Analytics in the UKI:
- Pyramid executives, customers, partners, media and technology industry analysts celebrated a $120 million Series E funding round at a special event at Tower Bridge in May.
- Tom Warren, a veteran technology professional and former professional rugby player, was appointed Managing Director for the company’s UKI operations.
- Bill Clayton joined Pyramid in the new role of Vice President, Global Partnerships. He has more than 20 years of enterprise software experience. Clayton has held positions with global technology leaders including IBM and Oracle. He lives in the UK.
- Hayley Munro was appointed Vice President of Global Customer Success. This newly created role provides unified, company-wide management of this critical function under one executive. She lives in the UK.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Bill Clayton, Vice President of Global Partner Sales, Pyramid Analytics: “Channel partnerships are an essential cornerstone of Pyramid’s growth strategy. Our highly productive and effective work with channel partners has forged a host of mutually beneficial relationships that have driven growth for all involved across the UKI. Channel partners are at the core of Pyramid’s business model. The growth and expansion of the company is firmly embedded with our channel partners.”
About Pyramid Analytics
Pyramid is what’s next in analytics. The award-winning Pyramid Decision Intelligence Platform delivers insights for faster, optimized decisions by providing direct access to any data, enabling governed self-service for any person, and meeting any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. This enables a strategic, enterprise-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005245/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom